Please login to the form below

Not currently logged in

Keytruda shows significant and meaningfully improvement in kidney cancer

Merck announces results from its phase 3 KEYNOTE-564 trial

Merck and Co

Merck, known as MSD outside the United States and Canada, yesterday announced results from its pivotal phase 3 KEYNOTE-564 trial evaluating Keytruda, its anti-PD-1 therapy.

The trial met its primary endpoint of disease-free survival (DFS) for the potential adjuvant treatment of patients with renal cell carcinoma (RCC) following the surgical removal of a kidney or following nephrectomy and resection of metastatic lesions.

The interim analysis was conducted by an independent Data Monitoring Committee, and Keytruda showed significant and meaningfully improvement compared with placebo in DFS.

Merck’s press release stated: ‘The trial will continue to evaluate overall survival (OS), a key secondary endpoint. The safety profile of Keytruda in this trial was consistent with that observed in previously reported studies.’

The press release added that results will be presented at an upcoming medical meeting and will be submitted to regulatory authorities.

Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories said: “Since its first approval in renal cell carcinoma nearly two years ago, Keytruda has become an important first-line treatment option in combination with axitinib for patients with advanced renal cell carcinoma.

“This new data is the result of our research to evaluate the role of Keytruda in helping patients with earlier stages of disease and are the first positive results for an anti-PD-1 therapy in the adjuvant treatment of patients with renal cell carcinoma. We look forward to sharing results of KEYNOTE-564 with the medical community and regulatory authorities as soon as possible.”

Keytruda is currently approved in the US, Europe and Japan in combination with axitinib for the first-line treatment of patients with advanced renal cell carcinoma.

Article by
Iona Everson

9th April 2021

From: Research



Subscribe to our email news alerts


Add my company
Branding Science

We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...

Latest intelligence

Whitepaper: Closing the gap with compelling healthcare communications
Want to learn how to close the distance between a person’s current health and their healthiest possible self?...
Healing the Healers
Because if we do not heal the healers, who is going to heal us?...
The (inevitable) digital transformation of Medical Affairs
It’s not a question of ‘if,’ it’s a question of ‘when.’...